Local research ethics committees should review their approval of prevention trialBMJ 1996; 312 doi: http://dx.doi.org/10.1136/bmj.312.7037.1036a (Published 20 April 1996) Cite this as: BMJ 1996;312:1036
- Catherine Read
- Science writer 33 Cockshutt Road, Beauchief, Sheffield S8 7DY
EDITOR,—R D Bulbrook's editorial discusses who should take tamoxifen and for how long.1 The British aTTom (adjuvant tamoxifen treatment offer more) trial aims to recruit up to 20000 women with primary breast cancer. Many of these women could receive at least seven years' treatment with tamoxifen—two years more than the National Cancer Institute considers routinely advisable for …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial